McDonald suggests one likely target: Albuferon, an interferon drug for hepatitis C now in phase 2 trials that belongs to Human Genome Sciences.

FORBES

McDonald suggests one likely target: Albuferon, an interferon drug for hepatitis C now in phase 2 trials that belongs to Human Genome Sciences (nasdaq: HGSI - news - people ).

FORBES: Gilead's Half-Empty Pipeline

Second, Bristol-Myers Squibb stopped a Phase II study of its BMS-094 for hepatitis C because of a serious safety issue.

FORBES: Big Pharma Failures Light the Way to Change

Many eye-vitamin formulations currently on the market are based on research conducted by the National Institutes of Health in a project called Age-Related Eye Disease Study, or AREDS. The first phase of the clinical trial, completed in 2001, found that a specific combination of vitamins C and E, along with beta-carotene and zinc, reduced the risk of age-related macular degeneration by as much as 25%.

WSJ: The Crucial Years for Protecting Your Eye Health